Home›Neurology› Obstructive sleep apnea is associated with higher blood T-tau and lower CSF amyloid-beta levels
Obstructive sleep apnea is associated with higher blood T-tau and lower CSF amyloid-beta levelsSleep Apnea Linked to Higher Alzheimer's Biomarkers in Blood
Frontiers in MedicinePublished September 21, 2026DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that OSA is associated with higher blood T-tau and lower CSF A-beta, but results are hypothesis-generating.
This meta-analysis evaluates the relationship between obstructive sleep apnea (OSA) and Alzheimer's disease (AD) related biomarkers in blood and cerebrospinal fluid (CSF). The study synthesizes data comparing OSA patients to non-OSA controls to identify specific biomarker signatures associated with sleep-disordered breathing.
Key findings include significantly higher levels of blood T-tau (SMD = 1.48; 95% CI [0.33, 2.62], p = 0.011) and blood T-A-beta (SMD = 0.66; 95% CI [0.34, 0.97], p < 0.01) in patients with OSA. Conversely, CSF A-beta40 (SMD = -1.13; 95% CI [-1.65, -0.60], p < 0.01) and CSF A-beta42 (SMD = -1.23; 95% CI [-1.84, -0.63], p < 0.01) were significantly lower in the OSA group. No significant differences were observed for blood A-beta40, blood A-beta42, blood A-beta42/A-beta40 ratio, blood P-tau, CSF A-beta42/A-beta40 ratio, CSF T-tau, or CSF P-tau.
The authors note significant limitations, including high heterogeneity, predominantly cross-sectional designs, and low-to-very-low GRADE certainty for most outcomes. Because of these factors and the lack of consistent alterations in P-tau or the CSF A-beta42/A-beta40 ratio, the findings are considered hypothesis-generating rather than conclusive. Clinical application is currently limited by the lack of a direct signature of established AD neuropathology.
How this fits prior evidence
This meta-analysis addresses a gap in understanding the impact of sleep-related disorders on Alzheimer's disease biomarkers. While prior evidence noted that sleep disturbances and obstructive sleep apnea impact sleep architecture and seizure thresholds in epilepsy, this study specifically examines the biochemical markers of Alzheimer's disease in the context of OSA. The findings are currently hypothesis-generating due to low-to-very-low GRADE certainty.
Researchers analyzed data to see if obstructive sleep apnea (OSA) is linked to markers of Alzheimer's disease. The study compared people with OSA to those without the condition. They looked at specific proteins in both the blood and the cerebrospinal fluid (CSF) to see if there were measurable differences.
The results showed that people with sleep apnea had significantly higher levels of T-tau and T-beta in their blood. However, other markers like P-tau and certain ratios in the spinal fluid did not show a clear link. Because the study used a variety of different reports and many were only snapshots in time, the evidence is not yet strong enough to prove a direct cause.
These findings are currently used to help form new ideas for future research. Because the data quality is currently low to very low, these results are not yet enough to change how doctors treat sleep apnea or Alzheimer's. It is a starting point for understanding how sleep issues might relate to brain health.
What this means for you:
Sleep apnea is linked to higher blood markers for Alzheimer's, but more research is needed to confirm a link.
Common questions
What did the study find about sleep apnea and Alzheimer's?
The study found that people with obstructive sleep apnea had significantly higher levels of T-tau and T-beta in their blood. However, other markers like P-tau and certain ratios in the spinal fluid did not show a significant difference compared to people without sleep apnea.
Is this finding a proven cause of Alzheimer's?
No, the study does not prove that sleep apnea causes Alzheimer's. Because the data comes from different types of studies and many were only snapshots in time, the results are currently considered hypothesis-generating rather than conclusive.
How certain are the results of this study?
The certainty of the results is currently low to very low for most outcomes. Because of this, the findings are not yet enough to change standard medical practices, but they provide a starting point for future research into the link between sleep and brain health.
PurposeThis study aimed to clarify the relationship between obstructive sleep apnea (OSA) and Alzheimer's disease (AD)-related biomarkers—specifically amyloid β (Aβ) and tau proteins—in blood and cerebrospinal fluid (CSF) through a systematic review and meta-analysis.MethodsPubMed, Web of Science (WOS), Embase, and Cochrane Library were searched from database inception to December 30, 2024 (PROSPERO registration: CRD420251148709). Studies reporting blood or CSF levels of Aβ40, Aβ42, total Aβ (T-Aβ), total tau (T-tau), or phosphorylated tau (P-tau) in patients with OSA vs. non-OSA controls were included. A random-effects model was employed for all meta-analyses. The risk of bias was assessed using appropriate validated tools.ResultsThirteen studies (seven blood, six CSF) were included. In blood, OSA patients showed significantly higher T-Aβ (SMD = 0.66, 95% CI [0.34, 0.97], I2 = 0%, p < 0.01) and T-tau (SMD = 1.48, 95% CI [0.33, 2.62], I2 = 93.6%, p = 0.011). No significant differences were found for blood Aβ40, Aβ42, Aβ42/Aβ40 ratio, or P-tau. In CSF, patients with OSA had significantly lower Aβ40 (SMD = −1.13, 95% CI [−1.65, −0.60], I2 = 0%, p < 0.01) and Aβ42 (SMD = −1.23, 95% CI [−1.84, −0.63], I2 = 77.3%, p < 0.01), but no differences in Aβ42/Aβ40 ratio, T-tau, or P-tau.LimitationsHigh heterogeneity, pre-dominantly cross-sectional designs, low-to-very-low GRADE certainty for most outcomes, retrospective registration, and limited study numbers preclude causal inference and warrant cautious interpretation.ConclusionsThis exploratory meta-analysis revealed compartment-specific associations between certain AD-related biomarkers and OSA. However, given the low-to-very-low certainty of the available evidence and the substantial uncertainty reflected by prediction intervals that frequently crossed the null value, these findings should be regarded as hypothesis-generating rather than conclusive. Notably, the absence of consistent alterations in P-tau or the CSF Aβ42/Aβ40 ratio argues against a direct signature of established AD neuropathology. Future rigorously designed, large-scale prospective studies are warranted to determine whether these biomarker changes reflect early AD pathology or reversible physiological responses to OSA-related hypoxia and sleep fragmentation.Systematic review registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1148709, identifier CRD420251148709.
